ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
PCRX
|
Lower extremity nerve block
|
Phase 3
|
2022-09-21 00:00:00
|
Phase 3 trial data achieved the study's primary endpoint by demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl, noted September 21, 2022.
| 1 |
AMPH
|
Asthma
|
CRL
|
2016-12-27 00:00:00
|
CRL issued December 27, 2016.
| 0 |
FNCH
|
Clostridioides difficile infection
|
Phase 2
|
2022-06-01 00:00:00
|
Phase 2 data presented at DDW reported that 88.2% of participants were without CDI recurrence through 8 weeks in this post-hoc analysis, noted June 1, 2022.
| 1 |
ANIP
|
Urinary tract infections
|
Approved
|
2023-04-24 00:00:00
|
Approved April 24, 2023.
| 1 |
DERM
|
Papulopustular Rosacea
|
Phase 3
|
2023-07-11 00:00:00
|
Phase 3 topline data achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues, noted July 11, 2023.
| 1 |
OVID
|
Dravet Syndrome / Lennox-Gastaut Syndrome
|
Phase 3
|
2023-04-27 00:00:00
|
Phase 3 data reported that 78% of patients tolerated the highest dose level well with sustained reduction in frequency of drop seizures, noted April 27, 2023.
| 1 |
NCNA
|
Advanced biliary tract cancer
|
Phase 3
|
2022-03-02 00:00:00
|
Independent Data Monitoring Committee (IDMC) concluded that trial was unlikely to achieve its primary objective and that treatment did not into an overall survival benefit, noted March 2, 2022.
| 1 |
AERI
|
Dry eye disease
|
Phase 2b
|
2022-04-26 00:00:00
|
Phase 2b results reported that statistically significant improvements were reported with signs and symptoms following treatment, noted April 24, 2022.
| 1 |
CLVS
|
Endometrial Cancer
|
Phase 2
|
2022-06-07 00:00:00
|
Phase 2 data reported that 23 subjects had clinical benefit, with 1 (4%) with CR, 9 (39%) with PR, and 13 (57%) with stable disease as best response, noted June 7, 2022.
| 0 |
NVO
|
Type 1 and type 2 diabetes
|
Phase 3
|
2017-09-29 00:00:00
|
Approved September 29, 2017.
| 1 |
ORIC
|
Multiple myeloma
|
Phase 1b
|
2023-11-02 00:00:00
|
Phase 1b data from ASH abstract reported that ORIC-533 was very well tolerated, with 5 patients experiencing a total of 10 treatment-related adverse events (TRAEs), noted November 2, 2023.
| 1 |
AZN
|
Non-small cell lung cancer (NSCLC)
|
Phase 3
|
2023-10-23 00:00:00
|
Phase 3 reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors , noted October 23, 2023.
| 1 |
HRMY
|
Fragile X syndrome
|
Phase 2/3
|
2022-05-13 00:00:00
|
Phase 2/3 long-term data reported that sustained improvement in ABC-CFXS Social Avoidance from baseline, noted May 13, 2022.
| 1 |
LLY
|
Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphomas (NHL); mantle cell lymphoma
|
Phase 1/2
|
2021-12-12 00:00:00
|
Phase 1/2 updated data reported an overall response rate (ORR) of 68% including 2 complete responses, noted December 12, 2021.
| 0 |
BMY
|
Ovarian Cancer - First-line maintenance treatment
|
Phase 3
|
2022-06-06 00:00:00
|
Additional Phase 3 data reported that median PFS for the HRD-positive patient population treated with rucaparib was 28.7 months, noted June 6, 2022.
| 1 |
RHHBY
|
Ovarian cancer
|
Approved
|
2018-06-13 00:00:00
|
FDA approval announced June 13, 2018.
| 1 |
ENSC
|
Nasal Opioid Abuse
|
Phase 1
|
2022-10-31 00:00:00
|
HAP data reported that PF614 powder produced significantly lower peak "drug liking" when compared with intranasal crushed IR oxycodone, noted October 31, 2022.
| 0 |
MEIP
|
High-risk Myelodysplastic Syndrome (MDS)
|
Phase 2
|
2018-05-31 00:00:00
|
Phase 2 commencement of dosing announced June 14, 2017 - analysis from first stage released May 31, 2018 - trial to expand enrollment.
| 0 |
MRK
|
Renal cell carcinoma
|
Approved
|
2019-04-22 00:00:00
|
FDA approval announced April 22, 2019.
| 1 |
REGN
|
Respiratory syncytial virus (RSV)
|
Phase 3
|
2017-08-14 00:00:00
|
Phase 3 data released August 14, 2017 - primary endpoint not met.
| 0 |
REGN
|
COVID-19 (Anti-viral antibody)
|
Phase 2/3
|
2021-09-30 00:00:00
|
Phase 3 trial met primary endpoint, with 36% reduced risk of death by day 29, and 56% reduced risk in patients who were seronegative. Of 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients, noted September 30, 2021.
| 1 |
JAZZ
|
Acute lymphoblastic leukemia (ALL)
|
Approved
|
2021-06-30 00:00:00
|
FDA approval announced June 30, 2021.
| 1 |
ANAB
|
Acne
|
Phase 2
|
2022-03-14 00:00:00
|
Phase 2 data reported that the trial did not meet the primary or secondary endpoints, noted March 14, 2022.
| 1 |
MNOV
|
COVID-19 / acute respiratory distress syndrome (ARDS)
|
Phase 2
|
2022-06-08 00:00:00
|
Phase 2 trial met one co-primary endpoint with statistical significants with 71% of the treated group free from respiratory failure at Day 7, noted June 8, 2022.
| 1 |
IPSEY
|
Pancreatic cancer
|
Phase 3
|
2022-11-09 00:00:00
|
Phase 3 data met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated. Key secondary efficacy outcomes of progression-free survival (PFS) also showed significant improvement over the comparator arm, noted November 9, 2022.
| 1 |
MRK
|
Pneumococcal Conjugate Vaccine
|
Phase 3
|
2023-07-27 00:00:00
|
Phase 3 trial met primary endpoints, noted July 27, 2023.
| 0 |
JNCE
|
Solid tumors
|
Phase 1
|
2023-03-16 00:00:00
|
Phase 1 data report 5 durable responses, with 4 being confirmed responses, noted March 16, 2023.
| 0 |
AMRX
|
Advanced prostatic cancer
|
Approved
|
2022-11-02 00:00:00
|
FDA Abbreviated New Drug Application (ANDA) approval on November 2, 2022.
| 1 |
NAVB
|
Rheumatoid arthritis
|
Phase 2b
|
2022-09-15 00:00:00
|
Phase 2b data reported that the quantitative TIL uptake in the hands and wrists of patients is proportional to the amount of macrophage involvement in an individual RA patient's joint inflammation, noted September 15, 2022.
| 0 |
RHHBY
|
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
|
Approved
|
2020-07-30 00:00:00
|
FDA approval announced July 30, 2020.
| 1 |
AFMD
|
CD30-positive peripheral T cell lymphoma (PTCL)
|
Phase 2
|
2023-04-16 00:00:00
|
Phase 2 presentation at AACR reported an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in the ITT population, noted April 16, 2023.
| 1 |
ABBV
|
Relapsed or refractory multiple myeloma
|
Phase 3
|
2023-09-29 00:00:00
|
Phase 3 data reported that it showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone; however, the results did not reach statistical significance, noted September 29, 2023.
| 1 |
ADAP
|
Esophageal and esophagogastric junction cancers
|
Phase 2
|
2022-11-08 00:00:00
|
Phase 2 data reported that ORR has increased to 37% from 33%, and the median duration of response has increased to ~20 weeks from approximately 12 weeks, noted November 8, 2022.
| 0 |
SNY
|
Acid sphingomyelinase deficiency (ASMD)
|
Phase 3
|
2020-01-30 00:00:00
|
Phase 3 data met two independent primary endpoints- January 30, 2020. Combination endpoint was not met.
| 0 |
RHHBY
|
Cancer related diarrhea (CRD)
|
Phase 2
|
2021-12-10 00:00:00
|
Phase 2 results reported that CID occurred significantly less (23%) in the crofelemer group during cycle 1 and crofelemer patients were 1.8 times more likely than control patients to have their diarrhea resolved, noted December 10, 2021.
| 0 |
NVS
|
Acute heart failure
|
Phase 3
|
2017-03-22 00:00:00
|
Phase 3 data released March 22, 2017 - primary endpoints not met.
| 0 |
MRK
|
Metastatic non-small cell lung cancer (NSCLC)
|
Phase 3
|
2022-02-08 00:00:00
|
Phase 3 trial did not meet primary endpoints of overall survival, safety profile was consistent with that observed in the overall JAVELIN clinical development program, noted February 8, 2022.
| 1 |
GSK
|
HIV
|
Approved
|
2019-04-08 00:00:00
|
FDA approval announced April 8, 2019.
| 1 |
FRTX
|
Autoimmune and inflammatory diseases
|
Phase 1
|
2023-03-07 00:00:00
|
Phase 1 SAD and MAD topline results reported that trial met the primary endpoint, noted March 7, 2023.
| 0 |
DNLI
|
Hunter syndrome MPS II
|
Phase 1/2
|
2023-08-30 00:00:00
|
Additional data from SSIEM reported that data demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkers, noted August 30, 2023.
| 1 |
ARAV
|
Growth hormone deficiency, or GHD - pediatric
|
Phase 3
|
2017-09-21 00:00:00
|
Phase 3 top-line data released September 21, 2017 - primary endpoint not met.
| 0 |
ICPT
|
Primary Biliary Cholangitis (PBC)
|
Phase 2
|
2023-06-23 00:00:00
|
Phase 2 interim data presented at EASL showed combination of OCA 5-10 mg + bezafibrate 400 mg normalized a range of biomarkers of PBC (ALP, total bilirubin, GGT, ALT and AST) in 58% of patients at 12 weeks, noted June 23, 2023.
| 1 |
BHC
|
Acne vulgaris
|
Approved
|
2023-10-20 00:00:00
|
Approved on October 20, 2023.
| 1 |
SYBX
|
Cirrhotic patients with elevated ammonia
|
Phase 1/2
|
2019-08-20 00:00:00
|
Development to be discontinued due to lack of efficacy.
| -1 |
RHHBY
|
SMA type 1/2/3 switching
|
Phase 2
|
2021-06-11 00:00:00
|
Phase 2 data reported a sustained >2-fold increase in median SMN protein levels versus baseline in all patients who received prior treatment, noted June 11, 2021.
| 1 |
PRQR
|
Leber's Congenital Amaurosis (LCA) - Genetic blindness
|
Phase 2/3
|
2022-04-13 00:00:00
|
Phase 2/3 analysis found that benefit was observed in mean change from baseline in BCVA, noted April 13, 2022.
| 1 |
KOD
|
Treatment-Naive Wet Age-Related Macular Degeneration (AMD)
|
Phase 3
|
2023-10-13 00:00:00
|
Phase 3 data presented at the Retina Society meeting reported a favorable safety profile with low rates of intraocular inflammation and no cases of intraocular inflammation with vasculitis or vascular occlusion, noted October 13, 2023.
| 1 |
BMY
|
Relapsed or refractory (R/R) large B-cell lymphoma
|
Approved
|
2021-02-05 00:00:00
|
FDA approval announced February 5, 2021.
| 1 |
AVIR
|
Dengue
|
Phase 2
|
2023-04-17 00:00:00
|
Additional Phase 2 data presented at ECCMID reported that AT-752 was well tolerated and had no clinically relevant effects on cardiac repolarization, heart rate, PR or QRS intervals, noted April 17, 2023.
| 1 |
MRNA
|
Personalized cancer vaccine, high-risk melanoma
|
Phase 2
|
2023-10-23 00:00:00
|
Phase 2 additional data presented at ESMO reported that local recurrence was more common in MRs; MNRs had more distant events. This trend was supported by stronger separation in DMFS vs RFS between MRs and MNRs, noted October 23, 2023.
| 1 |
PFE
|
Migraine
|
Approved
|
2023-03-10 00:00:00
|
Approved March 10, 2023.
| 1 |
BMRN
|
Phenylketonuria (PKU)
|
Phase 1/2
|
2021-09-06 00:00:00
|
Phase 1/2 clinical hold announced September 6, 2021.
| 0 |
PFE
|
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
|
Approved
|
2017-12-19 00:00:00
|
Approval announced December 19, 2017.
| 1 |
ZYME
|
HER2-expressing Gastrointestinal Cancers (Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer)
|
Phase 2
|
2023-01-19 00:00:00
|
Phase 2 data presented at ASCO Gastrointestinal Cancers Symposium reported an overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months, noted January 19, 2023.
| 1 |
PFE
|
Renal cell carcinoma (RCC)
|
Approved
|
2019-05-14 00:00:00
|
FDA Approval announced May 14, 2019.
| 1 |
TSHA
|
Rett syndrome
|
Phase 1/2
|
2023-08-24 00:00:00
|
FDA granted Fast Track Designation (FTD), noted August 24, 2023.
| 0 |
XCUR
|
Merkel cell carcinoma / Cutaneous squamous cell carcinoma
|
Phase 1/2
|
2021-08-05 00:00:00
|
Phase 1b/2 interim data noted overall response rate (ORR) of 21% in all evaluable MCC patients - August 5, 2021.
| 1 |
BBIO
|
Molybdenum cofactor deficiency type A
|
Approved
|
2021-02-26 00:00:00
|
FDA approved February 26, 2021.
| 1 |
SUPN
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 3
|
2020-02-25 00:00:00
|
Phase 3 trial did not meet primary endpoint.
| 1 |
MDWD
|
Venous leg ulcers (VLU’s)
|
Phase 2
|
2022-05-12 00:00:00
|
Phase 2 results reported that both primary and key secondary endpoints were met, noted May 12, 2022.
| 0 |
ALVR
|
BK viremia
|
Phase 2
|
2023-02-15 00:00:00
|
Phase 2 final results showed an even greater antiviral effect with treatment in patients with BK viral load ≥10,000 copies/mL at screening and in the biweekly posoleucel dosing group, identifying a dosing regimen and patient population to advance into a future trial., noted February 15, 2023.
| 1 |
RLMD
|
Major Depressive Disorder (MDD)
|
Phase 3
|
2023-09-20 00:00:00
|
Phase 3 results showed that patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment, noted Septemeber 20, 2023.
| 1 |
TEVA
|
Osteoarthritis pain of the hip or knee
|
Phase 3
|
2020-08-05 00:00:00
|
Phase 3 data achieved the co-primary endpoints for fasinumab 1 mg monthly. Fasinumab every two months did not reach statistical significance - August 5, 2020.
| 1 |
OPK
|
Adults - growth hormone deficiency
|
Phase 3
|
2016-12-30 00:00:00
|
Phase 3 data released December 30, 2016 - primary endpoint not met.
| 0 |
IMVIQ
|
Diffuse Large B Cell Lymphoma (DLBCL)
|
Phase 2
|
2023-02-13 00:00:00
|
Phase 2b initial response data showed that from 6/8 patients evaluable for efficacy; 3 patients showed confirmed complete responses, 1 patient was assessed with stable disease as best response and 2 patients were assessed with progressive disease as best response; and 2 patients with poor level of baseline functionality (ECOG ≥ 2) failed to stay on study through to the first scan and therefore could not be evaluated, noted February 13, 2023.
| 1 |
TERN
|
Non-alcoholic steatohepatitis (NASH)
|
Phase 1
|
2022-11-04 00:00:00
|
Phase 1 data reported that TERN-501 was generally well tolerated and exhibited dose-dependent pharmacokinetics with low variability, noted November 4, 2022
| 1 |
MRK
|
Advanced renal cell carcinoma (RCC)
|
Phase 3
|
2023-08-17 00:00:00
|
Phase 3 trial met primary endpoint, noted August 18, 2023.
| 0 |
MRK
|
Metastatic non-small cell lung cancer (NSCLC)
|
Phase 3
|
2023-09-22 00:00:00
|
Phase 3 data reported that there was not an improvement in OS for patients who received KEYTRUDA plus LENVIMA compared to docetaxel, noted September 22, 2023.
| 1 |
AMGN
|
Plaque psoriasis
|
Phase 3
|
2022-04-18 00:00:00
|
Phase 3 data reported that trial met primary endpoint, noted April 18, 2022.
| 0 |
MRNA
|
COVID-19
|
Phase 3
|
2023-10-24 00:00:00
|
Phase 3 trial of mRNA-1083 in adults 50 years initiated, noted October 24, 2023.
| 0 |
ABBV
|
Parkinson's disease
|
CRL
|
2023-03-22 00:00:00
|
CRL issued by FDA on March 22, 2023.
| 0 |
JAZZ
|
Acute Myeloid Leukemia (AML)
|
Phase 1b
|
2022-12-12 00:00:00
|
Phase 1b subgroup analysis reported that complete remission (CR) was achieved by 14/17 (82%) patients with a FLT3 ITD mutation and by 5/6 (83%) patients with a FLT3 TKD mutation, noted December 12, 2022.
| 1 |
IGXT
|
Pain
|
PDUFA priority review
|
2023-09-19 00:00:00
|
In response to the CRL, Xiromed submitted to the FDA an Amendment to the ANDA, requesting priority review, noted September 19, 2023. In an Amendment Acknowledgement received from the FDA by the company, the FDA granted priority review with a Generic Drug User Fee Act (GDUFA) date for review of the Amendment of March 8, 2024, unless the Agency determines that an inspection is required. Alternatively, if the FDA determines that an inspection is required, the GDUFA goal date is July 8, 2024.
| 0 |
CRDF
|
KRAS-Mutated Colorectal Cancer
|
Phase 1/2
|
2022-09-10 00:00:00
|
Phase 1b/2 data presented at ESMO showed durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, noted September 10, 2022.
| 1 |
ACRS
|
Rheumatoid arthritis (RA)
|
Phase 2a
|
2021-01-19 00:00:00
|
Phase 2a 12-week data released January 19, 2021 - generally well tolerated.
| 1 |
MRK
|
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
|
Approved
|
2017-05-18 00:00:00
|
Approved May 18, 2017.
| 1 |
ALNA
|
Gout in chronic kidney disease (CKD)
|
Phase 2a
|
2022-08-10 00:00:00
|
Cohort A and B initial data reported that the data was not statistically significant, noted August 10, 2022.
| 0 |
IVVD
|
COVID-19 Prevention
|
Phase 3
|
2023-09-11 00:00:00
|
Phase 3 dosing initiated, noted September 11, 2023.
| 0 |
RHHBY
|
Pemphigus vulgaris
|
Approved
|
2018-06-07 00:00:00
|
Approval announced June 7, 2018.
| 1 |
PBYI
|
Extended adjuvant treatment of early stage HER2-positive breast cancer
|
Phase 2
|
2021-12-13 00:00:00
|
Phase 2 dose escalation final findings reported that Neratinib DE + loperamide PRN during the first 2 weeks of treatment was associated with the lowest rates of grade 3 diarrhea (13.3%) and diarrhea-related discontinuations (3.3%) compared with all other anti-diarrheal strategies investigated in the trial, noted December 13, 2021.
| 1 |
ALKS
|
Schizophrenia, bipolar
|
Approved
|
2021-06-01 00:00:00
|
FDA approval announced June 1, 2021.
| 1 |
CMRX
|
Acute lung injury (ALI) in COVID-19
|
Phase 2
|
2021-05-06 00:00:00
|
Phase 2 initial data released May 6, 2021. One patients died in DSTAT arm.
| 0 |
SRNE
|
Lumbosacral radicular pain (sciatica)
|
Phase 3
|
2022-05-05 00:00:00
|
Phase 3 data presented at ASIPP reported that treatment reduced sciatica pain with an extended effect for up to 99 days following a single injection, noted May 5, 2022.
| 1 |
LEGN
|
Relapsed/Refractory Multiple Myeloma (R/R MM)
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 26-month data reported that median PFS and OS were NR; 24-month PFS and OS rates were 52.6% and 74.2%, respectively, noted December 12, 2022.
| 0 |
AZN
|
Dyslipidaemia
|
Phase 2b
|
2022-04-04 00:00:00
|
Phase 2b study met its primary and secondary endpoints; ION449 was generally well tolerated, noted April 4, 2022
| 1 |
GSK
|
Multiple myeloma
|
Approved
|
2020-08-05 00:00:00
|
FDA approval granted August 5, 2020.
| 1 |
GSK
|
Ovarian cancer
|
Approved
|
2020-04-29 00:00:00
|
FDA Approval announced April 29, 2020.
| 1 |
MITO
|
Geographic atrophy (GA) / Age-related macular degeneration (AMD)
|
Phase 2b
|
2022-05-02 00:00:00
|
Phase 2b top-line data reported that trial did not meet primary endpoint, noted May 2, 2022.
| 1 |
RHHBY
|
Urothelial carcinoma
|
Phase 3
|
2019-09-30 00:00:00
|
Phase 3 data at ESMO 2019 noted median PFS=8.2 versus 6.3 months; hazard ratio (HR)=0.82.
| 0 |
NVO
|
Type 2 diabetes
|
Phase 3
|
2022-10-03 00:00:00
|
Phase 3a trial met primary endpoint, noted October 3, 2022.
| 0 |
LIAN
|
Ulcerative Colitis (UC)
|
Phase 1b
|
2022-08-03 00:00:00
|
Phase 1b top-line data reported that no serious adverse events (SAEs) were reported, noted August 3, 2022.
| 0 |
MRNA
|
Covid-19 Omicron Booster
|
Approved
|
2023-09-11 00:00:00
|
FDA approved on September 11, 2023.
| 1 |
LLY
|
Atopic Dermatitis
|
Phase 1
|
2023-10-13 00:00:00
|
Phase 1b data presented at EADV 2023 showed dose-dependent efficacy reported across all endpoints for REZPEG demonstrating a rapid onset of action and continuing benefit for 36 weeks after 12-week treatment period, noted October 13, 2023.
| 1 |
TARS
|
Lyme disease
|
Phase 1
|
2022-12-15 00:00:00
|
Phase 1 data data showed that treatment was well tolerated and safety data supports progression to Phase 2a (Carpo), noted December 15, 2022.
| 1 |
SGEN
|
Acute myeloid leukemia (AML) - cancer
|
Phase 3
|
2017-06-19 00:00:00
|
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
| -1 |
PLX
|
Gaucher disease
|
Approved
|
2012-05-01 00:00:00
|
Approved May 1, 2012.
| 1 |
MREO
|
Solid tumors
|
Phase 1/2
|
2021-11-30 00:00:00
|
Phase 1b/2 interim data showed that the dose was well tolerated with a favorable safety profile. One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set
| 1 |
SAGE
|
Major Depressive Disorder (MDD)
|
Phase 3
|
2019-12-05 00:00:00
|
Phase 3 data did not meet primary endpoint - December 5, 2019.
| 1 |
IMUX
|
Primary Sclerosing Cholangitis
|
Phase 2
|
2021-02-18 00:00:00
|
Phase 2 data released February 18, 2021. Primary objective of therapeutic benefit achieved in 27.3% of patients.
| 1 |
MRK
|
Small cell lung cancer (SCLC)
|
CRL
|
2021-03-01 00:00:00
|
FDA Approval announced June 18, 2019. Approval withdrawn March 1, 2021 due to not meeting post-marketing requirements following accelerated approval.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.